Pharmacodynamic Biomarker

Pharmacodynamic biomarker quantitates pharmaceutical target engagement predicting therapeutic efficacy. Receptor occupancy assessment determines target saturation. Pathway activation quantitation indicates mechanism engagement. Biomarker response precedes clinical benefit enabling early assessment. Dose-biomarker relationships characterise target engagement kinetics.

Regulatory submissions employ biomarker evidence supporting efficacy. Clinical outcomes correlate with biomarker changes. Biomarker-driven dosing optimises therapy. Post-approval monitoring confirms biomarker predictions. Emerging imaging enables visualised biomarker assessment.